177 related articles for article (PubMed ID: 25424920)
1. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
Roberts C; Green T; Hess E; Matys K; Brown MJ; Haupt RM; Luxembourg A; Vuocolo S; Saah A; Antonello J
Hum Vaccin Immunother; 2014; 10(8):2168-74. PubMed ID: 25424920
[TBL] [Abstract][Full Text] [Related]
2. Multiplexed serologic assay for nine anogenital human papillomavirus types.
Opalka D; Matys K; Bojczuk P; Green T; Gesser R; Saah A; Haupt R; Dutko F; Esser MT
Clin Vaccine Immunol; 2010 May; 17(5):818-27. PubMed ID: 20237197
[TBL] [Abstract][Full Text] [Related]
3. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
[TBL] [Abstract][Full Text] [Related]
4. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
[TBL] [Abstract][Full Text] [Related]
5. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
[TBL] [Abstract][Full Text] [Related]
6. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.
Kahn JA; Xu J; Kapogiannis BG; Sleasman JW
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):241-245. PubMed ID: 28291048
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.
Nygård M; Saah A; Munk C; Tryggvadottir L; Enerly E; Hortlund M; Sigurdardottir LG; Vuocolo S; Kjaer SK; Dillner J
Clin Vaccine Immunol; 2015 Aug; 22(8):943-8. PubMed ID: 26084514
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types.
Nolan KM; Seaton B; Antonello J; Zhang Y; Cook L; Delfino K; Rubinstein LJ; Cheon K; Group T; Luxembourg A; Dubey S
mSphere; 2023 Apr; 8(2):e0096221. PubMed ID: 36926984
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.
Scherpenisse M; Schepp RM; Mollers M; Mooij SH; Meijer CJ; Berbers GA; van der Klis FR
Clin Vaccine Immunol; 2013 Aug; 20(8):1329-32. PubMed ID: 23740920
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Mei W; McNeil S; Money D; Dionne M; Karunakaran KP; Palefsky JM; Dobson S; Ogilvie G; Petric M
Clin Vaccine Immunol; 2011 Mar; 18(3):418-23. PubMed ID: 21248158
[TBL] [Abstract][Full Text] [Related]
14. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.
Opalka D; Lachman CE; MacMullen SA; Jansen KU; Smith JF; Chirmule N; Esser MT
Clin Diagn Lab Immunol; 2003 Jan; 10(1):108-15. PubMed ID: 12522048
[TBL] [Abstract][Full Text] [Related]
16. Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine.
Zhang X; Meng D; Li H; Li X; Li J; Hu P; Zhao L; Wang R; Zhao C; Luo C; Gu W; Gai W; Wang Y; Xie L
J Med Virol; 2023 Aug; 95(8):e29050. PubMed ID: 37635425
[TBL] [Abstract][Full Text] [Related]
17. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.
Dias D; Van Doren J; Schlottmann S; Kelly S; Puchalski D; Ruiz W; Boerckel P; Kessler J; Antonello JM; Green T; Brown M; Smith J; Chirmule N; Barr E; Jansen KU; Esser MT
Clin Diagn Lab Immunol; 2005 Aug; 12(8):959-69. PubMed ID: 16085914
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18.
Trevisan A; Wissing MD; Dagenais C; Forest P; Ramanakumar AV; Burchell AN; Franco EL; Coutlée F; Couillard M
J Gen Virol; 2021 May; 102(5):. PubMed ID: 34043499
[TBL] [Abstract][Full Text] [Related]
19. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
[TBL] [Abstract][Full Text] [Related]
20. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.
Wentzensen N; Rodriguez AC; Viscidi R; Herrero R; Hildesheim A; Ghosh A; Morales J; Wacholder S; Guillen D; Alfaro M; Safaeian M; Burk RD; Schiffman M
J Infect Dis; 2011 Jul; 204(1):94-102. PubMed ID: 21628663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
